# Janusz Gumprecht

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/janusz-gumprecht/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,034 |
| Field | Diabetes Treatment and Management |
| h-index | 34 |
| i10-index | 79 |
| Last Known Institution | Medical University of Silesia |
| OpenAlex ID | https://openalex.org/A5057777286 |
| ORCID iD | 0000-0001-7091-2118 |
| Works | 307 |

## Researcher papers

- [Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial](https://scholariq.org/papers/oral-semaglutide-versus-empagliflozin-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes-and/)
- [Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes](https://scholariq.org/papers/effect-of-insulin-degludec-vs-insulin-glargine-u100-on-hypoglycemia-in-patients/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-by-sodium/)
- [Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists](https://scholariq.org/papers/inflammation-and-oxidative-stress-in-diabetic-kidney-disease-the-targets-for/)
- [Importance of Observational Studies in Clinical Practice](https://scholariq.org/papers/importance-of-observational-studies-in-clinical-practice/)
- [Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/anti-interleukin-21-antibody-and-liraglutide-for-the-preservation-of-cell/)
- [2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland](https://scholariq.org/papers/2019-guidelines-on-the-management-of-diabetic-patients-a-position-of-diabetes/)
- [Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota](https://scholariq.org/papers/metabolic-associated-fatty-liver-disease-mafld-diabetes-and-cardiovascular/)
- [Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach](https://scholariq.org/papers/risk-factors-for-cardiovascular-disease-in-patients-with-metabolic-associated/)
- [Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial](https://scholariq.org/papers/kidney-and-survival-outcomes-with-semaglutide-by-ckd-severity-in-the-flow-trial/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

## Researcher university

- [Medical University of Silesia](https://scholariq.org/institutions/medical-university-of-silesia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.